Literature DB >> 9808536

A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation.

Y Hosoi1, H Miyachi, Y Matsumoto, H Ikehata, J Komura, K Ishii, H J Zhao, M Yoshida, Y Takai, S Yamada, N Suzuki, T Ono.   

Abstract

ATM and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) have been shown to have sequences homologous to the catalytic domains of mammalian phosphatidylinositol 3-kinase (PI3-kinase). In order to determine the contribution of ATM and DNA-PKcs to the increased sensitivity of cells to DNA-damaging agents observed in the presence of PI3-kinase inhibitors, we examined the effects of a PI3-kinase inhibitor, wortmannin, on cellular sensitivity to bleomycin (BLM), mitomycin C (MMC), X-irradiation and ultraviolet (UV)-irradiation using 2 human tumor cell lines (T98G and A172), a human fibroblast cell line (LM217), an ataxia telangiectasia (AT) cell line (AT3BISV), a scid murine cell line (SCF) and a control murine cell line (CBF). Wortmannin sensitized all of the cells, including AT3BISV and SCF, to BLM and X-irradiation, but not to MMC or UV-irradiation. Hypersensitivity to BLM and X-irradiation and normal sensitivity to MMC and UV-irradiation are characteristic phenotypes of both AT and scid mice. DNA-dependent protein kinase (DNA-PK) activity was suppressed by wortmannin to 45-65% of the control values in all of the cells except SCF, in which DNA-PK activity was not detected. Wortmannin also induced radioresistant DNA synthesis, which is a cellular phenotype of AT, in T98G and SCF cells, but did not change the DNA synthesis rates after X-irradiation in AT3BISV. Our data suggest that wortmannin decreases the activities of both the ATM protein and DNA-PK, indicating that it might be of use as a sensitizing agent for radiotherapy and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808536     DOI: 10.1002/(sici)1097-0215(19981123)78:5<642::aid-ijc19>3.0.co;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation.

Authors:  Tracey A Dobbs; John A Tainer; Susan P Lees-Miller
Journal:  DNA Repair (Amst)       Date:  2010-10-28

2.  Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses.

Authors:  R Daniel; R A Katz; G Merkel; J C Hittle; T J Yen; A M Skalka
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors.

Authors:  David M Weingeist; Jing Ge; David K Wood; James T Mutamba; Qiuying Huang; Elizabeth A Rowland; Michael B Yaffe; Scott Floyd; Bevin P Engelward
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

4.  Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63.

Authors:  Xin Li; Jiguang Tian; Qiyu Bo; Ka Li; Hongliang Wang; Ting Liu; Jianmin Li
Journal:  Tumour Biol       Date:  2015-06-25

5.  The Human T-Cell Leukemia Virus Type 1 Basic Leucine Zipper Factor Attenuates Repair of Double-Stranded DNA Breaks via Nonhomologous End Joining.

Authors:  Amanda W Rushing; Kimson Hoang; Nicholas Polakowski; Isabelle Lemasson
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

6.  Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma.

Authors:  Y Shen; Y Wang; K Sheng; X Fei; Q Guo; J Larner; X Kong; Y Qiu; J Mi
Journal:  Cell Death Dis       Date:  2011-12-08       Impact factor: 8.469

7.  Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity.

Authors:  Y Hosoi; Y Matsumoto; M Tomita; A Enomoto; A Morita; K Sakai; N Umeda; H-J Zhao; K Nakagawa; T Ono; N Suzuki
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

8.  The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

Authors:  Alexandre Arcaro; Ana S Guerreiro
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.